DACAB: Ticagrelor and Aspirin Improve Vein Graft Patency

According to this Chinese study, dual antiplatelet therapy with ticagrelor and aspirin improves vein graft patency a year after surgery without increasing the risk for major bleeding.

DACAB: el ticagrelor y la aspirina mejoran la permeabilidad de los puentes venosos

 

Treatment with the P2Y12 inhibitor ticagrelor in combination with aspirin has been widely accepted for patients with acute coronary syndrome undergoing angioplasty. However, there were no related data regarding surgical revascularization.


Read also: Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Vascular Disease”.


This new information is of great interest, since 25% of all vein grafts are occluded after a year and about half of them are occluded after 10 years.

 

The DACAB study, presented at the American Heart Association (AHA) 2017 Scientific Sessions, enrolled 500 patients who underwent myocardial revascularization surgery and treatment with ticagrelor, aspirin, or both. All patients were started on their therapy within 24 hours after the surgery.

 

Vein graft patency at one year was superior in patients in the dual antiplatelet therapy group compared with those receiving aspirin alone (88.7% vs. 76.5%; p = 0.006).


Read also: The End of Aspirin for Anticoagulated Patients Undergoing PCI”.


The rate of combined events was highest in the aspirin monotherapy arm (5.4%) compared with the ticagrelor alone arm (2.4%), and the combination therapy group (1.8%).

 

Due to certain study design limitations, many experts said that these results are interesting but preliminary.

 

Original title: Efficacy and Safety of a Dual Ticagrelor Plus Aspirin Antiplatelet Strategy After Coronary Artery Bypass Grafting: The DACAB Randomized Clinical Trial.

Reference: Zhao Q. American Heart Association 2017 Scientific Sessions. 12 de noviembre del 2017.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...